Hansa Biopharma and NewBridge Pharmaceuticals

Date: January 6, 2024

January 06, 2024, Hansa and NewBridge Pharmaceuticals have formed a partnership to enable supply of Hansa's novel treatment Idefirix® to kidney transplant patients in the Middle East and North Africa (MENA. The new collaboration is rooted in the existing European conditional marketing authorization for Idefirix and pending application for marketing authorization in the respective MENA markets for desensitization treatment in kidney transplantation.